Dallas, Texas 07/31/2014 (FINANCIALSTRENDS) – Johnson & Johnson (NYSE:JNJ) announced on Wednesday that it would recall its special surgical devices for the treatment of fibroids called Ethicon morcellators fearing spread of cancer. The company had stopped the sale and distribution of Ethicon morcellators since April of this year. The recall follows the current review by the US regulatory body – U.S. Food and Drug Administration as well as doctors and community members. The company has been asking doctors and organizations which have purchase the power morecellators to return the surgical device, which has been driven by controversy ever since its launch.
Johnson & Johnson (NYSE:JNJ) unit Ethicon has had to discontinue this device which was introduced amidst expectations that it would allow for non-invasive techniques to treat uterine growth in women called as fibroid. The morcellator’s sharp blades function was to cut or mince-out uterine growth, for easy removal via non-invasive processes. Doctors were finding it an effective procedure to handle hysterectomies as well.
But the issue in an otherwise effective terminator of fibroid was that it cut-up non-diagnosed cancer cells as well. This placed the patient undergoing this procedure under great risk as malignant cancer cells which were undetected too would be chopped by the spinning blade allowing the unintentional spread of the dreaded disease. It would also lead to further deterioration of patient condition, was a concern raised by FDA.
Johnson & Johnson (NYSE:JNJ) Ethicon spokesperson in a statement issued via e-mail stated that, “Due to this continued uncertainty, Ethicon believes that a market withdrawal of Ethicon morcellation devices is the appropriate course of action at this time until further medical guidelines are established and/or new technologies are developed to mitigate the risk.” FDA has announced that the devices are not be used by doctors until it had reviewed the device and offered further direction on its use.